IFNG and incontinentia pigmenti: Treatment with recombinant IFN-γ restored immune function as indicated by increased HLA-DR expression in those with IP, increased ex-vivo cytokine production (e.g., TNF-α, IL-17, IL-22), and increased total leukocyte counts.